A Missouri judge on Friday granted final approval to Bayer's $7.25 billion settlement of lawsuits alleging its Roundup weedkiller causes cancer, overruling objections that payouts to individual victims would be too low and clearing the way for compensation to tens of thousands of claimants.
Judge Timothy Boyer of a state court in St Louis found the settlement “fair, reasonable and adequate.” He rejected arguments from some lawyers representing cancer patients that payouts, expected to average between $10,000 and $165,000 depending on age, illness severity and exposure duration, were too low compared with earlier settlements. The judge said further delays could force victims, including those with terminal cancer, to wait “an indeterminate number of years” to be paid.
Bayer had faced about 65,000 claims in US state and federal courts before the settlement, which was announced in February. The agreement covers people who say they developed non-Hodgkin lymphoma after using Roundup, and also those who may be diagnosed in the future after previous exposure to the weedkiller. Bayer will pay up to $7.25 billion into a special fund over 21 years.
The approval comes after the US Supreme Court in June dealt a major blow to Roundup plaintiffs, ruling 7-2 that federal pesticide regulations barred failure-to-warn claims brought under state law, narrowing a central legal path for lawsuits. A Missouri jury also found in Bayer's favor in a separate Roundup case in October.
“The court’s final approval is a decisive milestone in the company’s strategy to mitigate the risks of both pending and future Roundup litigation,” Bayer CEO Bill Anderson said in a statement. Christopher Seeger, a lawyer for many of the plaintiffs, said the Supreme Court decision had limited victims' ability to pursue claims. “We look forward to getting this relief into the hands of all Roundup victims as quickly as possible,” he said.
Bayer has long maintained that Roundup and its active ingredient, glyphosate, are safe and that decades of studies showed no link to cancer. The World Health Organization's cancer agency classified glyphosate as “probably carcinogenic” in 2015, while the US Environmental Protection Agency says it is unlikely to cause cancer when used as directed.
The settlement excludes some lawsuits still pending in federal court. Bayer has said about 200 of those cases were still being litigated and that the Supreme Court decision gave it strong defenses. The company has already set aside $16 billion for Roundup-related legal costs and seen its shares fall 46% since it bought Monsanto for $63 billion in 2018. The settlement could still be appealed.
Analysis
Why This Matters
- Tens of thousands of cancer victims and their families will begin receiving compensation, ending a decade-long legal ordeal for claimants who faced years of uncertainty.
- The approval removes a major overhang on Bayer's stock, which had fallen 46% since the Monsanto takeover, and may allow the company to move past litigation that had cost it $16 billion in provisions.
- The Supreme Court's June ruling narrows the ability of plaintiffs to sue chemical companies under state failure-to-warn claims, potentially reshaping future product-liability battles.
Background
Bayer inherited Roundup liability when it bought Monsanto for $63 billion in 2018. Roundup, introduced in 1974, contains glyphosate, one of the world's most widely used weedkillers. The company had already settled much of the litigation for $10.9 billion in 2020 but failed to secure court approval for a separate $1.25 billion deal covering future claims. Some lawsuits had resulted in huge jury awards, including $2.1 billion to plaintiffs in Georgia. The debate over glyphosate's safety intensified after a major study that had supported Roundup's safety for decades was withdrawn in 2025 over undisclosed Monsanto involvement.
Key Perspectives
Judge Timothy Boyer: Found the settlement fair, reasonable and adequate, saying delays could leave terminally ill patients waiting years.
Bayer CEO Bill Anderson: Called the approval a decisive milestone in mitigating litigation risks.
Christopher Seeger, lawyer for plaintiffs: Welcomed the decision, saying it delivers guaranteed compensation to victims who waited more than a decade.
Some lawyers representing cancer patients: Argued payouts were too low because earlier claimants received more; the judge overruled their objections.
What to Watch
- Whether any party appeals Friday's approval order, which could delay payouts.
- The outcome of the roughly 200 cases still being litigated in federal court, where Bayer says the Supreme Court decision gives it strong defenses.
- Bayer's next steps on Roundup: it has already removed glyphosate from versions sold to US consumers and may push for federal pre-emption on warning labels.